Uterine Cancer

Soslow, Robert A.; Oliva, Esther

doi:10.1007/978-1-60327-044-1_4

Search citation statements

Order By: Relevance

Paper Sections

Select...

Anatomopathology1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The macroscopic appearance of SML is in 90% of cases that of a single nodule forming an intramyometrial mass with a well defined growth boundary [3]. On cross-section, the tumor is pink to pale gray in color with necrotic and hemorrhagic areas.…”

Section: Anatomopathologymentioning

confidence: 99%

Diagnostic Criteria for Uterine Sarcoma: Review of the Literature

-¹,

-²,

-³

et al. 2023

IJFMR

View full text Add to dashboard Cite

Uterine leiomyosarcomas are rare and have a poor prognosis, particularly at the metastatic stage. The rarity of this tumor justiﬁe that patients be referred to referral centers aﬁn order to have optimal diagnostic and therapeutic management. Anatomopathologic diagnosis is based on the demonstration of three features: necrosis, cytologic atypia, and mitoses within a smooth muscle proliferation. Chemotherapy probably has a place in the adjuvant management. In locally advanced or metastatic forms, the prognosis is poor, with an overall survival of about 12-14 months despite first-line polychymic therapy that gives response rates of about 30%. Anti-angiogenic drugs and hormone therapy have their place in the therapeutic arsenal. Multimodal management can improve the prognosis of some patients

show abstract

Section: Anatomopathologymentioning

confidence: 99%